AgomAb Therapeutics NV (AGMB)
AgomAb Therapeutics NV (AGMB) Stock Price, Analysis & Data
| Bid | 10.2 |
| Market Cap | 686.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -81.6M |
| Beta | n/a |
| EPS (ttm) | -1.56 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.7 |
| P/B (ttm) | 5.33 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 17.76 |
| Volume | 240,606 |
| Avg. Volume (20D) | 97,141 |
| Open | 14.24 |
| Previous Close | 14.11 |
| Day's Range | 13.76 - 14.29 |
| 52-Week Range | 8.75 - 17.82 |
| Analyst | Strong Buy |
| Price Target | 34 (143.73%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AGMB
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule i...
Financial Performance
In 2025, AgomAb Therapeutics NV's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -62.55M, an increase of 35.19%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for AGMB stock is "Strong Buy". The 12-month stock price forecast is 34, which is upside of 143.73% from the latest price.
Stock Forecasts
